Organization · Venture Capital
age1
age1 is a venture capital firm based in the United States that funds early-stage companies focused on longevity and healthy aging. The firm supports contrarian founders developing innovative biotech solutions to address aging-related challenges.
Overview
What age1 does
What age1 is
age1 is a venture capital firm based in the United States that funds early-stage companies focused on longevity and healthy aging. The firm supports contrarian founders developing innovative biotech solutions to address aging-related challenges.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Venture Capital
- Founded
- Founded in 2023
- Approximate age
- About 3 years
- Structured capabilities
- Funder
- Last reviewed
- April 10, 2026
Official channels
Find age1 elsewhere
Open the official website or a supported primary organization account.
Capability profile
age1 as a funder
Investment thesis
age1 focuses on funding companies that aim to extend healthy lifespan through longevity research, supporting contrarian founders developing innovative therapeutics and technologies targeting aging and age-related diseases.
Focus narrative
age1 invests primarily in early-stage companies, including pre-seed, seed, and series A rounds. The organization is well-capitalized to support its portfolio companies through later funding rounds, with investments ranging from $500,000 to $4 million. The focus is on exceptional founders globally who are developing therapeutics, tools, and technologies that target aging and age-related diseases.
Value beyond capital
age1 provides significant value-add to its portfolio companies by leveraging its deep expertise in longevity research and a strong network within the biotech industry. The organization supports founders not only with capital but also with strategic guidance and resources to navigate the complexities of developing innovative therapies and technologies.
Terms and economics
- Typical check
- $500,000–$4,000,000
Focus and fit
- Stages
- Pre-seed · Seed · Series A
- Regions
- Global · United States
Availability
- Currently deploying
- Yes
Portfolio and track record
- Recorded portfolio count
- 23
Portfolio context
age1 has backed several notable companies in the longevity sector, including: ALXO: First-in-class foundational checkpoint immunotherapies. DBTX: Regenerative and gene therapies to restore hearing and balance. MTCR: Therapies for gastrointestinal and liver disease. DTIL: Novel gene editing technology for new classes of medicines. UBX: Therapeutics aimed at slowing, halting, or reversing diseases of aging.
Common questions
What to know about age1
Upseed classifies age1 under the Venture Capital organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
April 10, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.